CSBR
Price
$6.25
Change
-$0.00 (-0.00%)
Updated
Jun 23, 02:50 PM (EDT)
Capitalization
88.39M
23 days until earnings call
Intraday BUY SELL Signals
MREO
Price
$0.32
Change
-$0.00 (-0.00%)
Updated
Jun 23, 04:59 PM (EDT)
Capitalization
52.15M
56 days until earnings call
Intraday BUY SELL Signals
Interact to see
Advertisement

CSBR vs MREO

CSBR vs MREO Comparison Chart in %
loading
loading
View a ticker or compare two or three
VS
CSBR vs. MREO commentary
Jun 24, 2026

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is CSBR is a Hold and MREO is a Hold.

Interact to see
Advertisement
COMPARISON
Comparison
Jun 24, 2026
Stock price -- (CSBR: $6.36 vs. MREO: $0.33)
Brand notoriety: CSBR and MREO are both not notable
Both companies represent the Biotechnology industry
Current volume relative to the 65-day Moving Average: CSBR: 52% vs. MREO: 33%
Market capitalization -- CSBR: $88.39M vs. MREO: $52.15M
CSBR [@Biotechnology] is valued at $88.39M. MREO’s [@Biotechnology] market capitalization is $52.15M. The market cap for tickers in the [@Biotechnology] industry ranges from $118.47B to $0. The average market capitalization across the [@Biotechnology] industry is $2B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

CSBR’s FA Score shows that 1 FA rating(s) are green whileMREO’s FA Score has 1 green FA rating(s).

  • CSBR’s FA Score: 1 green, 4 red.
  • MREO’s FA Score: 1 green, 4 red.
According to our system of comparison, MREO is a better buy in the long-term than CSBR.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

CSBR’s TA Score shows that 6 TA indicator(s) are bullish while MREO’s TA Score has 7 bullish TA indicator(s).

  • CSBR’s TA Score: 6 bullish, 4 bearish.
  • MREO’s TA Score: 7 bullish, 3 bearish.
According to our system of comparison, MREO is a better buy in the short-term than CSBR.

Price Growth

CSBR (@Biotechnology) experienced а +0.39% price change this week, while MREO (@Biotechnology) price change was +10.37% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was +5.89%. For the same industry, the average monthly price growth was +2.09%, and the average quarterly price growth was +1952.22%.

Reported Earning Dates

CSBR is expected to report earnings on Jul 16, 2026.

MREO is expected to report earnings on Aug 18, 2026.

Industries' Descriptions

@Biotechnology (+5.89% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
CSBR($88.4M) has a higher market cap than MREO($52.1M). CSBR YTD gains are higher at: -7.887 vs. MREO (-21.598). CSBR has higher annual earnings (EBITDA): -772K vs. MREO (-34.43M). MREO has more cash in the bank: 36.2M vs. CSBR (7.13M). MREO has less debt than CSBR: MREO (0) vs CSBR (4.89M). CSBR has higher revenues than MREO: CSBR (57.9M) vs MREO (500K).
CSBRMREOCSBR / MREO
Capitalization88.4M52.1M170%
EBITDA-772K-34.43M2%
Gain YTD-7.887-21.59837%
P/E Ratio35.88N/A-
Revenue57.9M500K11,580%
Total Cash7.13M36.2M20%
Total Debt4.89M0-
FUNDAMENTALS RATINGS
CSBR vs MREO: Fundamental Ratings
CSBR
MREO
OUTLOOK RATING
1..100
6357
VALUATION
overvalued / fair valued / undervalued
1..100
89
Overvalued
60
Fair valued
PROFIT vs RISK RATING
1..100
100100
SMR RATING
1..100
9999
PRICE GROWTH RATING
1..100
5864
P/E GROWTH RATING
1..100
131
SEASONALITY SCORE
1..100
8550

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

MREO's Valuation (60) in the null industry is in the same range as CSBR (89) in the Biotechnology industry. This means that MREO’s stock grew similarly to CSBR’s over the last 12 months.

MREO's Profit vs Risk Rating (100) in the null industry is in the same range as CSBR (100) in the Biotechnology industry. This means that MREO’s stock grew similarly to CSBR’s over the last 12 months.

MREO's SMR Rating (99) in the null industry is in the same range as CSBR (99) in the Biotechnology industry. This means that MREO’s stock grew similarly to CSBR’s over the last 12 months.

CSBR's Price Growth Rating (58) in the Biotechnology industry is in the same range as MREO (64) in the null industry. This means that CSBR’s stock grew similarly to MREO’s over the last 12 months.

MREO's P/E Growth Rating (1) in the null industry is in the same range as CSBR (13) in the Biotechnology industry. This means that MREO’s stock grew similarly to CSBR’s over the last 12 months.

TECHNICAL ANALYSIS
Technical Analysis
CSBRMREO
RSI
ODDS (%)
Bearish Trend 2 days ago
82%
Bearish Trend 2 days ago
86%
Stochastic
ODDS (%)
Bearish Trend 2 days ago
71%
Bullish Trend 2 days ago
78%
Momentum
ODDS (%)
Bullish Trend 2 days ago
71%
Bullish Trend 2 days ago
88%
MACD
ODDS (%)
Bullish Trend 2 days ago
73%
Bullish Trend 2 days ago
83%
TrendWeek
ODDS (%)
Bearish Trend 2 days ago
77%
Bullish Trend 2 days ago
81%
TrendMonth
ODDS (%)
Bullish Trend 2 days ago
72%
Bullish Trend 2 days ago
83%
Advances
ODDS (%)
Bullish Trend 12 days ago
72%
Bullish Trend 6 days ago
80%
Declines
ODDS (%)
Bearish Trend 6 days ago
74%
Bearish Trend 8 days ago
86%
BollingerBands
ODDS (%)
Bearish Trend 2 days ago
76%
Bearish Trend 2 days ago
79%
Aroon
ODDS (%)
Bullish Trend 6 days ago
71%
Bullish Trend 2 days ago
90%
View a ticker or compare two or three
Interact to see
Advertisement
CSBR
Daily Signal:
Gain/Loss:
MREO
Daily Signal:
Gain/Loss:
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
MFs / NAMEPrice $Chg $Chg %
LSIUX15.70N/A
N/A
ClearBridge International Value IS
TESRX26.19N/A
N/A
Franklin Mutual Shares R
TCMGX19.32N/A
N/A
Nuveen Quant Mid Cap Growth A
RYIAX142.37N/A
N/A
Rydex Internet H
FIJYX44.14N/A
N/A
Fidelity Advisor Biotechnology Z

CSBR and

Correlation & Price change

A.I.dvisor tells us that CSBR and OABI have been poorly correlated (+25% of the time) for the last year. This A.I.-generated data suggests there is low statistical probability that CSBR and OABI's prices will move in lockstep.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To CSBR
1D Price
Change %
CSBR100%
+0.71%
OABI - CSBR
25%
Poorly correlated
-1.28%
MREO - CSBR
24%
Poorly correlated
+5.59%
PLUR - CSBR
24%
Poorly correlated
N/A
PHAT - CSBR
24%
Poorly correlated
-1.75%
GLUE - CSBR
24%
Poorly correlated
+1.91%
More